3A-register for outpatient therapy with RAS inhibitors in patients with arterial hypertension in Germany [3A-Register Zur Ambulanten Therapie Mit RAS-Inhibitoren in Patienten Mit Arterieller Hypertonie in Deutschland]

Trial Profile

3A-register for outpatient therapy with RAS inhibitors in patients with arterial hypertension in Germany [3A-Register Zur Ambulanten Therapie Mit RAS-Inhibitoren in Patienten Mit Arterieller Hypertonie in Deutschland]

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Aliskiren (Primary) ; ACE inhibitors; Angiotensin receptor antagonists; Antihypertensives
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms 3A Registry
  • Most Recent Events

    • 20 Apr 2016 Results (retrospective analysis, n = 3772) assessing aliskiren in diabetic patients published in the Journal of Clinical Hypertension (Greenwich).
    • 21 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top